Memphis Pharmaceuticals & Chemical Industries Past Earnings Performance
Past criteria checks 4/6
Memphis Pharmaceuticals & Chemical Industries has been growing earnings at an average annual rate of 135.5%, while the Pharmaceuticals industry saw earnings growing at 3.1% annually. Revenues have been growing at an average rate of 10.6% per year. Memphis Pharmaceuticals & Chemical Industries's return on equity is 152.1%, and it has net margins of 15.1%.
Key information
135.5%
Earnings growth rate
135.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 9.8% |
| Revenue growth rate | 10.6% |
| Return on equity | 152.1% |
| Net Margin | 15.1% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Memphis Pharmaceuticals & Chemical Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 585 | 88 | 75 | 0 |
| 31 Dec 22 | 597 | 92 | 77 | 0 |
| 30 Sep 22 | 573 | 82 | 81 | 0 |
| 30 Jun 22 | 551 | 74 | 72 | 0 |
| 31 Mar 22 | 529 | 37 | 73 | 0 |
| 31 Dec 21 | 507 | 33 | 69 | 0 |
| 30 Sep 21 | 510 | 39 | 86 | 0 |
| 30 Jun 21 | 518 | 42 | 76 | 0 |
| 31 Mar 21 | 506 | 38 | 28 | 0 |
| 31 Dec 20 | 506 | 33 | 30 | 0 |
| 30 Sep 20 | 510 | 24 | 25 | 0 |
| 30 Jun 20 | 488 | 17 | 24 | 0 |
| 31 Mar 20 | 463 | -3 | 56 | 0 |
| 31 Dec 19 | 437 | -4 | 46 | 0 |
| 30 Sep 19 | 401 | -11 | 22 | 0 |
| 30 Jun 19 | 363 | -25 | 22 | 0 |
| 31 Mar 19 | 347 | -33 | 24 | 0 |
| 31 Dec 18 | 337 | -45 | 21 | 0 |
| 30 Sep 18 | 339 | -52 | 21 | 0 |
| 30 Jun 18 | 340 | -47 | 21 | 0 |
| 31 Mar 18 | 291 | -67 | 23 | 0 |
| 31 Dec 17 | 266 | -56 | 22 | 0 |
| 30 Sep 17 | 255 | -42 | 21 | 0 |
| 30 Jun 17 | 248 | -34 | 21 | 0 |
| 31 Mar 17 | 302 | 2 | 17 | 0 |
| 31 Dec 16 | 321 | 2 | 18 | 0 |
| 30 Sep 16 | 313 | 0 | 20 | 0 |
| 30 Jun 16 | 354 | 0 | 19 | 0 |
| 31 Mar 16 | 348 | 2 | 53 | 0 |
| 31 Dec 15 | 386 | 0 | 53 | 0 |
| 30 Sep 15 | 409 | -4 | 51 | 0 |
| 30 Jun 15 | 392 | -10 | 51 | 0 |
| 31 Mar 15 | 417 | -13 | 52 | 0 |
| 31 Dec 14 | 411 | -12 | 49 | 0 |
| 30 Sep 14 | 402 | -7 | 49 | 0 |
| 30 Jun 14 | 398 | 0 | 48 | 0 |
| 31 Mar 14 | 424 | 4 | 50 | 0 |
| 31 Dec 13 | 406 | 7 | 35 | 0 |
| 30 Sep 13 | 395 | 5 | 49 | 0 |
| 30 Jun 13 | 397 | 5 | 48 | 0 |
Quality Earnings: MPCI has high quality earnings.
Growing Profit Margin: MPCI's current net profit margins (15.1%) are higher than last year (7.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MPCI has become profitable over the past 5 years.
Accelerating Growth: Insufficient data to compare MPCI's past year earnings growth to its 5-year average.
Earnings vs Industry: MPCI earnings growth over the past year (135.5%) exceeded the Pharmaceuticals industry 27.9%.
Return on Equity
High ROE: Whilst MPCI's Return on Equity (152.13%) is outstanding, this metric is skewed due to their high level of debt.